HER3 as Therapeutic Target in Lung Cancer: Evaluating the Rationale and Clinical Evidence for Targeted Treatment to Manage EGFR Resistance

Thursday, December 7, 2023

3:00PM – 4:00PM ET

Please note this program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.

PROGRAM OVERVIEW

This Grand Rounds series will to help you evaluate the role of HER3 biology in the management of advanced non-small cell lung cancer (NSCLC), including tumors resistant to EGFR tyrosine kinase inhibition (TKI); summarize the clinical development of HER3-targeted therapeutics in the management of NSCLC in patients with advanced NSCLC with EGFR-activating mutations; and recognize the importance of multidisciplinary monitoring and management of treatment-related adverse events in patients receiving HER3-targeted antibody-drug conjugates. This interactive program combines didactic instruction with case-based discussions and animations.

PRESENTING FACULTY

Helena A. Yu, MD
Thoracic Oncologist & Early Drug Development Specialist
Memorial Sloan Kettering Cancer Center
New York, NY

TARGET AUDIENCE

This innovative and community-based educational activity is designed to meet the educational needs of US-based community and academic oncologists, pathologists, pulmonologists, oncology nurse practitioners and physician assistants, oncology nurses, and clinical and board-certified oncology pharmacists to ensure confidence in the management of NSCLC.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Evaluate the role of HER3 biology in the management of advanced NSCLC and EGFR-resistant NSCLC, including the rationale for combination HER3-targeted and EGFR-targeted therapy
  • Summarize the clinical development of HER3-targeted antibodies in the management of NSCLC in patients with advanced NSCLC with EGFR-activating mutations
  • Recognize the importance of multidisciplinary monitoring and management strategies in the management of treatment-related adverse events in patients receiving HER3-targeted antibody-drug conjugates

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

NURSES (ANCC) CREDIT DESIGNATION

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected].

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.